A Study of LY3532226 in Participants With Obesity

Last updated: January 16, 2026
Sponsor: Eli Lilly and Company
Overall Status: Completed

Phase

1

Condition

Obesity

Diabetes Prevention

Treatment

Placebo

LY3532226

Clinical Study ID

NCT06557356
18835
J2V-MC-GZLD
  • Ages 18-65
  • All Genders

Study Summary

The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY3532226 in participants with obesity. Blood tests will be performed to check how much LY3532226 gets into the bloodstream and how long it takes the body to eliminate it following weekly or monthly administration. Part A of the study will last approximately 16 weeks, excluding screening period. Part B of the study will last approximately 20 weeks, excluding the screening period. Part C of the study will last approximately 8 weeks, excluding the screening period.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Have a body weight not exceeding 150 kilograms (kg) or 330 pounds (lb) and body massindex (BMI) within the range of 30 to 40 kilogram per square meter (kg/m²)

  • Have had a stable body weight that is less than or equal to 5% change in body weightfor 3 months prior to screening and enrollment

Exclusion

Exclusion Criteria:

  • Have a lifetime history of a suicide attempt

  • Have a history or presence of psychiatric disorders, including a history of majordepressive disorder within the last 2 years

  • Have a baseline Patient Health Questionnaire-9 (PHQ-9) score of 15 or greater,and/or a score of 2 or greater for either of the first 2 questions on the PHQ-9questionnaire

  • Have a known clinically significant gastric emptying abnormality, have undergonegastric bypass surgery or restrictive bariatric surgery

  • Have taken approved or investigational medication for weight loss, within theprevious 3 months or 5 half-lives of study screening, whichever is earlier

  • Intend to use any weight-loss medications during study participation

  • Have obesity induced by other endocrinologic disorders or diagnosed monogenetic orsyndromic forms of obesity

Study Design

Total Participants: 132
Treatment Group(s): 2
Primary Treatment: Placebo
Phase: 1
Study Start date:
August 16, 2024
Estimated Completion Date:
December 12, 2025

Connect with a study center

  • Lilly Centre for Clinical Pharmacology

    Singapore, 138623
    Singapore

    Site Not Available

  • Lilly Centre for Clinical Pharmacology Pte. Ltd.

    Singapore, 138623
    Singapore

    Site Not Available

  • Lilly Centre for Clinical Pharmacology

    Singapore 1880252, 138623
    Singapore

    Site Not Available

  • Fortrea CRU, Inc.

    Daytona Beach, Florida 32117
    United States

    Site Not Available

  • Fortrea Clinical Research Unit

    Daytona Beach, Florida 32117
    United States

    Site Not Available

  • Fortrea Clinical Research Unit

    Daytona Beach 4152872, Florida 4155751 32117
    United States

    Site Not Available

  • Fortrea Clinical Research Unit

    Dallas, Texas 75247
    United States

    Site Not Available

  • Fortrea Clinical Research Unit

    Dallas 4684888, Texas 4736286 75247
    United States

    Site Not Available

  • Fortrea Clinical Research Unit

    Madison, Wisconsin 53704
    United States

    Site Not Available

  • Fortrea Clinical Research Unit

    Madison 5261457, Wisconsin 5279468 53704
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.